Evogene (EVGN) Financials: History & Chart

Evogene Ltd.(EVGN)

Biotechnology · Rehovot, HM

$0.40-0.01 (-1.91%)

Delayed quote: Oct 6, 2026, 9:44 AM EDT

About Evogene Ltd.

Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.

Rehovot, HM

52 employees

www.evogene.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Ofer Haviv

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	1.31M	347K	334K	314K	312K	884K	2.44M	1.61M	1.74M
Cost of Goods Sold	2.93M	355K	130K	2.28M	157K	136K	1.61M	755K	1.04M
Gross Profit	-1.62M	-8K	204K	-1.97M	155K	748K	830K	856K	698K
Gross Profit Margin	-123.9%	-2.3%	61.1%	-627.4%	49.7%	84.6%	34.0%	53.1%	40.1%
Total Operating Expenses	11.91M	2.43M	3.35M	3.24M	2.88M	3.82M	4.96M	5.42M	6.62M
Research & Development	6.27M	1.23M	1.84M	1.83M	1.38M	2.32M	3.21M	3.40M	3.31M
Selling, General & Administrative	5.44M	1.21M	1.54M	1.20M	1.50M	1.50M	1.94M	2.02M	3.31M
Operating Income (EBIT)	-13.53M	-2.44M	-3.15M	-5.21M	-2.72M	-3.07M	-4.13M	-4.57M	-5.92M
Operating Margin	-1035.0%	-703.5%	-943.1%	-1659.9%	-873.1%	-347.4%	-168.8%	-283.5%	-340.2%
Income Before Tax (EBT)	-15.56M	-1.59M	-5.91M	-5.34M	-2.73M	-3.53M	-2.99M	2K	-6.75M
Interest Income	2.96M	1.14M	1.17M	181K	465K	235K	1.60M	4.73M	2.07M
Interest Expense	4.86M	168K	3.88M	350K	453K	628K	464K	144K	2.89M
Other Income/Expense	-2.04M	850K	-2.76M	-126K	-4K	-457K	1.14M	4.57M	-827K
Net Income	-9.07M	-1.77M	-5.87M	-5.31M	3.87M	-4.46M	-2.59M	427K	-7.63M
Income Tax Expense	5K	0.00	4K	0.00	1K	1K	0.00	7K	1K
Net Profit Margin	-694.2%	-509.5%	-1757.5%	-1690.8%	1241.7%	-504.8%	-105.9%	26.5%	-438.5%
EBITDA	-12.63M	-2.29M	-2.95M	-4.95M	-2.44M	-2.78M	-3.55M	-3.97M	-5.71M
EBITDA Margin	-966.5%	-660.5%	-882.6%	-1576.1%	-783.0%	-314.6%	-145.1%	-246.7%	-328.2%
Depreciation & Amortization	895K	149K	202K	263K	281K	290K	579K	593K	209K
EPS Basic	-0.91	-0.14	-0.60	-0.61	0.44	-0.62	-0.38	0.06	-1.31
EPS Diluted	-0.91	-0.14	-0.60	-0.61	0.44	-0.62	-0.38	0.06	-1.31
Weighted Average Basic Shares	12.20M	12.20M	9.74M	8.72M	8.72M	7.23M	6.80M	6.80M	5.81M
Weighted Average Diluted Shares	12.20M	12.20M	9.74M	8.72M	8.72M	7.23M	6.80M	6.80M	5.81M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	3.85M	5.58M	2.98M	1.68M	930K	1.04M	753K	1.75M
Cost of Goods Sold	4.09M	2.38M	1.49M	909K	767K	574K	334K	1.45M
Gross Profit	-241K	3.20M	1.49M	766K	163K	466K	419K	295K
Gross Profit Margin	-6.3%	57.3%	50.0%	45.7%	17.5%	44.8%	55.6%	16.9%
Total Operating Expenses	13.79M	22.00M	23.72M	27.71M	31.12M	25.28M	21.59M	20.28M
Research & Development	7.99M	12.51M	16.20M	20.79M	21.13M	17.29M	15.79M	14.69M
Selling, General & Administrative	5.76M	8.98M	7.53M	10.41M	9.99M	7.99M	5.79M	5.60M
Operating Income (EBIT)	-14.03M	-18.80M	-22.23M	-26.94M	-30.95M	-24.81M	-21.17M	-19.99M
Operating Margin	-364.2%	-337.2%	-745.5%	-1608.4%	-3328.3%	-2386.0%	-2810.9%	-1144.2%
Income Before Tax (EBT)	-13.50M	-14.81M	-21.95M	-29.75M	-30.43M	-26.17M	-19.09M	-20.78M
Interest Income	2.47M	957K	1.25M	182K	291K	230K	759K	1.41M
Interest Expense	1.89M	124K	171K	241K	403K	269K	354K	141K
Other Income/Expense	536K	4.00M	285K	-2.81M	521K	-1.36M	2.08M	-793K
Net Income	-8.48M	-16.48M	-23.88M	-26.64M	-27.79M	-23.37M	-18.11M	-20.76M
Income Tax Expense	1K	9K	19K	90K	13K	32K	24K	30K
Net Profit Margin	-220.2%	-295.6%	-800.8%	-1590.3%	-2988.5%	-2247.5%	-2405.3%	-1188.2%
EBITDA	-12.89M	-17.42M	-20.93M	-24.36M	-28.72M	-22.09M	-18.40M	-17.97M
EBITDA Margin	-334.5%	-312.4%	-701.9%	-1454.4%	-3088.1%	-2123.8%	-2443.2%	-1028.6%
Depreciation & Amortization	1.14M	1.38M	1.30M	2.58M	2.23M	2.73M	2.77M	2.02M
EPS Basic	-1.08	-2.89	-5.23	-6.46	-0.68	-0.64	-0.70	-0.81
EPS Diluted	-1.08	-2.89	-5.23	-6.46	-0.68	-0.64	-0.70	-0.81
Weighted Average Basic Shares	7.87M	5.70M	4.57M	4.12M	41.01M	36.55M	25.75M	25.75M
Weighted Average Diluted Shares	7.87M	5.70M	4.57M	4.12M	41.01M	36.55M	25.75M	25.75M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.